<DOC>
	<DOC>NCT00973128</DOC>
	<brief_summary>The present study was designed as a randomized, single blind, placebo-controlled, study to evaluate the effect of 400 Âµg of recombinant human GM-CSF applied intralesionally and associated with half of the total dose of antimony in a reduced time schedule (20mgSbV/Kg/d for 10 days) as compared to the full dose of antimony (20mgSbV/Kg/d for 20 days) to treat cutaneous leishmaniasis ulcers.</brief_summary>
	<brief_title>Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis</brief_title>
	<detailed_description>This is a randomized, single blind placebo-controlled study in which the groups were selected from the cases presenting to the health post. The inclusion criteria were: age between 15 and 50 years, of either sex, diagnosis of cutaneous leishmaniasis of less than 60 days. The diagnostic criteria were the presence of a typical single cutaneous ulcer, localized on lower limbs, and a positive delayed type hypersensitivity test (DTH or Montenegro skin test) to Leishmania antigen.</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis, Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<criteria>Age between 15 and 50 years Either gender Diagnosis of cutaneous leishmaniasis Less than 60 days of disease Any history of prior antileishmania therapy Negative parasitology (aspirate/smear)or negative Montenegro test Pregnancy Age below 15 and above 50 years Other associated acute or chronic illnesses History of allergy to GMCSF and/or antimony HIV, HTLV1 infections or diabetes Administrative reasons: Lack of ability or willingness to give informed consent (patient and/or parent / legal representative) Anticipated nonavailability for study visits/procedures</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>